Original Articles
Vol. 6 No. 1 (2014): Reviews, Articles, Case Reports and Letters

A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE REACTIONS TO DRUG REGIME FOR MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS IN CENTRAL INDIA.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 1, 2014
5543
Views
1043
Downloads
3799
HTML
MDR TB, Causality assessment

Authors

Abstract

Objective: 1) To assess the adverse drug reactions of second line anti-tubercular drugs used to treat Multi-drug resistant Tuberculosis (MDR TB) in central India on the basis of causality, severity and avoidability scales. 2) To study the relationship of type of MDR TB (primary or secondary) and presence of diabetes mellitus (DM) with mean smear conversion time. Material and Methods: A prospective, observational study was carried out on diagnosed multidrug resistant tuberculosis patients enrolled for DOTS?Plus regimen at TB and Chest Disease Department from January to December 2012. They were followed for 9 months thereafter and encountered adverse drug reactions (ADRs) were noted along with the time of sputum conversion. The data were analysed by Chi-square or Fisher’s exact test and unpaired student’s‘t’ test. Results: Total 64 ADRs were reported in 55 patients out of total 110 patients (n = 110). As per the Naranjo causality assessment of ADRs, 7 patients had “definite” causal relation, 45 had “probable” causal relation and 3 had “possible” causal relation with drugs of DOTS Plus regime. As per the Hartwig’s severity assessment scale, there were total 7 ADRs in Level 1, 6 in Level 2, 33 in Level 3 and 9 in Level 4. Hallas avoidability assessment scale divided the ADRs as 3 being “Definitely avoidable”, 26 “Possibly avoidable”, 23 “Not avoidable” and 3 “unevaluable”. ). Mean sputum smear conversion time is significantly higher in patients with secondary type than that of primary type of MDR TB (p = 0.0001) and in patients with DM than those without DM (p <0.0001). Conclusion: ADRs were common in patients of MDR TB on DOTs-Plus drug regime. It was due to lack of availability of safer and equally potent drugs in DOTs-Plus drug regime compared to DOTS regime in non-resistant TB. The frequency and severity of ADRs can be reduced by strict vigilance about known and unknown ADRs, monitoring their laboratory and clinical parameters and instituting appropriate measures.

Keywords: Adverse drug reactions, Avoidability, Causality, DOTs-Plus, MDR TB, Severity.

Downloads

Download data is not yet available.

Citations

Ethics Approval

Original Article
Dr. Rohan C. Hire, MBBS, MD (Pharmacology), Department of Pharmacology, Government Medical College, Nagpur. Maharashtra. India-440003

Senior Resident Doctor,

Department of Pharmacology,

Government Medical College, Nagpur

India - 440003

Dr. A. S. Kale, MD, Professor and Head, Department of Pharmacology, Government Medical College, Nagpur. Maharashtra. India-440003
Professor and Head,
Department of Pharmacology,
Government Medical College, Nagpur.
Maharashtra.
India-440003
Dr. G. N. Dakhale, MD, Professor, Department of Pharmacology, Government Medical College, Nagpur. Maharashtra. India-440003
Professor,
Department of Pharmacology,
Government Medical College, Nagpur.
Maharashtra.
India-440003
Dr. Nilesh N. Gaikwad, MBBS, MD (Pharmacology), Department of Pharmacology, Government Medical College, Nagpur. Maharashtra. India-440003
Senior resident doctor,
Department of Pharmacology,
Government Medical College, Nagpur.
Maharashtra.
India-440003

How to Cite



“A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE REACTIONS TO DRUG REGIME FOR MULTI-DRUG RESISTANT PULMONARY TUBERCULOSIS IN CENTRAL INDIA”. (2014) Mediterranean Journal of Hematology and Infectious Diseases, 6(1), p. e2014061. doi:10.4084/mjhid.2014.061.